Basilea Pharmaceutica (BSLN) AI Stock Analysis

• Market Cap: CHF678.21M
• Dividend Yield: N/A
• Average Volume (3M): 42.41K
• Price to Earnings (P/E): 8.4
• Beta (1Y): 0.98
• Revenue Growth: 32.30%
• EPS Growth: 631.04%
• Country: CH
• Employees: 164
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): 4.70
• Shares Outstanding: 13,314,145
• 10 Day Avg. Volume: 47,097
• 30 Day Avg. Volume: 42,409
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF83.50
• Price Target Upside: 49.91% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 73 Outperform
• Price Target: CHF59.00 ▲(5.92% Upside)

Basilea Pharmaceutica's strong earnings call results and undervalued P/E ratio are significant positives. While financial performance showed robust growth, high liabilities and technical indicators suggest caution. Overall, the stock is poised for growth with strategic product expansions and funding support.

Positive Factors

Clinical Trials

Basilea initiated a Phase 3 study for its antifungal fosmanogepix, showcasing its potential to treat invasive mold infections with a novel mechanism of action.

Product Launch

Basilea's antibiotic Zevtera is being launched in the U.S. ahead of schedule, offering potential for early revenue generation from royalties and sales milestones.

Sales Milestones

Cresemba achieved a 20% year-over-year growth in global in-market sales, making it the largest branded antifungal for invasive fungal infections worldwide.

Negative Factors

Clinical Setbacks

Setbacks with clinical-stage candidates like fosmanogepix pose risks to Basilea's development pipeline.

Market Penetration

Potential challenges in achieving sufficient market penetration with ceftobiprole in the U.S. could impact revenue growth.

Partnership Optimization

Inability by Basilea's partners to optimize the value of isavuconazole and ceftobiprole globally is a significant risk.

Basilea Pharmaceutica Business Overview & Revenue Model

Company Description

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

How the Company Makes Money

Basilea Pharmaceutica makes money through the development, manufacturing, and commercialization of its pharmaceutical products. The company generates revenue through product sales, licensing agreements, and royalties. Key revenue streams include the sale of its proprietary drugs to healthcare providers and partnerships with other pharmaceutical companies for the development and distribution of its products. Additionally, Basilea engages in strategic collaborations and licensing agreements, where it may receive upfront payments, milestone payments, and royalties based on the commercialization success of its partnered products. The company's earnings are also influenced by its ability to effectively navigate regulatory approvals and market its products globally.

Basilea Pharmaceutica Financial Statement Overview

Summary

Basilea Pharmaceutica has demonstrated strong revenue growth and improved profitability with a significant net profit margin increase in 2024. The cash flow is robust, with a substantial free cash flow increase. However, balance sheet concerns persist due to high liabilities.

Income Statement

Basilea Pharmaceutica has shown strong revenue growth from 2023 to 2024 with an increase of 32.3%. The gross profit margin decreased from 2023 to 2024 due to a decline in gross profit. However, the net profit margin improved significantly to 37.2% in 2024, indicating better profitability. The EBIT and EBITDA margins also saw significant improvements, indicating enhanced operational efficiency.

Balance Sheet

The company has improved its balance sheet with positive stockholders' equity in 2024, moving from negative in previous years. The debt-to-equity ratio has improved as equity turned positive, and the equity ratio at 31.4% indicates a stronger financial position. However, high total liabilities relative to assets remain a concern.

Cash Flow

The cash flow statement shows a strong free cash flow growth of 449.6% from 2023 to 2024, indicating robust cash generation. The operating cash flow to net income ratio is healthy, supporting the company's profitability and cash generation capabilities. The free cash flow to net income ratio is also strong, reflecting efficient cash management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	208.54M	157.63M	147.76M	148.12M	127.63M
Gross Profit	169.86M	130.84M	120.96M	124.05M	103.58M
EBITDA	63.13M	23.18M	26.21M	6.72M	-2.24M
Net Income	77.59M	10.45M	12.15M	-6.83M	-14.72M
Balance Sheet
Total Assets	257.76M	173.29M	220.85M	247.27M	229.79M
Cash, Cash Equivalents and Short-Term Investments	120.71M	59.90M	86.57M	149.95M	167.28M
Total Debt	111.67M	128.61M	187.14M	218.96M	242.32M
Total Liabilities	176.76M	183.29M	241.56M	305.87M	331.84M
Stockholders Equity	81.00M	-10.00M	-20.71M	-58.61M	-102.05M
Cash Flow
Free Cash Flow	72.65M	13.21M	3.75M	-32.88M	-56.40M
Operating Cash Flow	74.36M	14.24M	7.06M	-32.02M	-54.13M
Investing Cash Flow	-1.01M	-1.03M	91.65M	3.58M	-34.96M
Financing Cash Flow	-13.16M	-57.30M	-45.25M	16.64M	45.07M

Basilea Pharmaceutica Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 55.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BSLN, the sentiment is Positive. The current price of 55.7 is above the 20-day moving average (MA) of 53.65, above the 50-day MA of 50.24, and above the 200-day MA of 44.66, indicating a bullish trend. The MACD of 2.24 indicates Negative momentum. The RSI at 61.64 is Neutral, neither overbought nor oversold. The STOCH value of 48.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:BSLN.

Basilea Pharmaceutica Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSLN	73 Outperform	CHF678.21M	8.37		―	32.30%	631.04%
KURN	64 Neutral	CHF1.05B	―	-6.44%	―	125.11%	69.27%
NWRN	64 Neutral	CHF137.53M	9.90		―	450.19%	―
IDIA	53 Neutral	CHF713.53M	―		―	57.35%	-474.25%
MOLN	52 Neutral	CHF119.71M	―	-40.40%	―	-66.82%	4.14%
Sector *	50 Neutral	AU$2.60B	3.65	-58.14%	2.69%	36.37%	13.78%
SANN	48 Neutral	CHF184.14M	2.58	-93.91%	―	-62.17%	-166.33%

Basilea Pharmaceutica Corporate Events

Basilea Secures $39 Million BARDA Funding for Antifungal Drug Development

Basilea Pharmaceutica announced that the US Biomedical Advanced Research and Development Authority (BARDA) has approved an additional $39 million in funding to support the development of its novel antifungal agents, Fosmanogepix and BAL2062. This funding will aid ongoing and upcoming Phase 3 and Phase 2 studies, addressing the high medical need for new antifungal treatments, especially for patients with weakened immune systems.

The most recent analyst rating on (CH:BSLN) stock is a Buy with a CHF95.00 price target. To see the full list of analyst forecasts on Basilea Pharmaceutica stock, see the CH:BSLN Stock Forecast page.